TY  - JOUR
AU  - Vogelgsang, Jonathan
AU  - Vukovich, Ruth
AU  - Wedekind, Dirk
AU  - Wiltfang, Jens
TI  - Higher Level of Mismatch in APOEε4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid.
JO  - ASN NEURO
VL  - 11
SN  - 1759-0914
CY  - London
PB  - Sage Publishing
M1  - DZNE-2020-07054
SP  - 175909141984552
PY  - 2019
AB  - Cerebrospinal fluid (CSF) biomarkers are widely used in the diagnosis of dementia. Even though there is a causal correlation between apolipoprotein E ( APOE) genotype and amyloid-beta (Aβ), the determination of APOE is currently not supported by national or international guidelines. We compared parallel measured CSF biomarkers of two independent laboratories from 126 patients who underwent clinical dementia diagnostics regarding the APOE genotype. APOE ε4 reduces Aβ1-42 (Aβ42) and Aβ42 to Aβ 1-40 ratio (Aβ42/40) but not total Tau or phospho-181 Tau CSF levels. Higher discordance rates were observed for Aβ42 and subsequently for Aβ42/40 in APOE ε4 carriers compared with noncarriers, and the correlation between the two laboratories was significantly lower for Aβ42 in APOE ε4 positive patients compared with patients without APOE ε4. These observations demonstrate that the evaluation of CSF Aβ biomarkers needs to be interpreted carefully in the clinical context. Different immunoassays, disparate cutoff values, and APOE should be respected.
KW  - Aged
KW  - Aged, 80 and over
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: genetics
KW  - Amyloid beta-Protein Precursor: cerebrospinal fluid
KW  - Apolipoproteins E: genetics
KW  - Biomarkers: cerebrospinal fluid
KW  - Female
KW  - Genotype
KW  - Heterozygote
KW  - Humans
KW  - Male
KW  - Middle Aged
LB  - PUB:(DE-HGF)16
C6  - pmid:31104469
C2  - pmc:PMC6535906
DO  - DOI:10.1177/1759091419845524
UR  - https://pub.dzne.de/record/140732
ER  -